Sabatini Brent sold $4K of VIR

Eli Lilly's Foundayo received a positive CHMP opinion for EU marketing authorization for weight management and type 2 diabetes. Roche's Enspryng gained FDA approval for thyroid eye disease. AstraZeneca partnered with insitro for AI-driven drug discovery in MASH and cardiomyopathies. The FDA launched a Rare Disease Framework Initiative to improve drug development for rare diseases. Gilead and Vir Biotechnology agreed to a $1.87 billion collaboration for masked T-cell engagers.

Gilead Sciences and Vir Biotechnology agreed to collaborate on developing T-cell engager therapies for solid tumors. Gilead will pay $90m upfront, including $65m in cash and $25m in equity, with up to $1.74bn in potential milestones. Gilead will lead development and commercialization, using Vir's PRO-XTEN technology and AI platform. This follows their 2021 hepatitis B drug collaboration and Vir's recent deal with Astellas.

Vir Biotechnology (VIR) and Gilead Sciences (GILD) have partnered to develop cancer immunotherapies. Vir will receive up to $135M upfront, including $65M cash and a $25M equity investment, with potential future payments of $1.74B. Vir's PRO-XTEN technology aims to reduce side effects and improve targeting. VIR is down 0.75%, GILD up 2.18%.

Vir Biotechnology (VIR) shares rose nearly 10% premarket on October 14, 2026, after announcing a $1.9B licensing deal with Gilead Sciences. The agreement focuses on Vir's PRO-XTEN technology for developing T-cell engager candidates. Vir's P/S ratio is 5.65, below its historical median of 17.0x, and its GF Score is 51, indicating moderate financial health. The company received $135M upfront, with potential milestone payments and royalties.

Vir Biotechnology and Gilead Sciences agreed to collaborate on cancer therapies for solid tumors, with a deal potentially worth up to $1.88 billion. Vir will receive $90 million upfront and could earn additional milestone payments and royalties. The partnership focuses on developing three drug candidates using Vir's technologies. Vir shares rose over 10% in premarket trading.

Vir Biotechnology (VIR) shares rose 10% premarket after a licensing deal with Gilead (GILD) for cancer drug development, potentially worth $1.9B. The agreement involves Vir's PRO-XTEN technology.